We invest in biomanufacturing and we focus on growing our portfolio of virotherapy medicines that meet the real needs of patients.
Products4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 virus Rigvir
The results show that there were no significant test item-related adverse events.
Based on the results, the no-observed-adverse-effect level (NOAEL) was considered to be the highest dose tested.
To finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.
For InvestorsThe aims of the project have been reached, and as a result a NOAEL (no adverse effect level) has been determined.
Read MoreRigvir's new API (Active pharmaceutical ingredient) center of manufacturing has received GMP (Good Manufacturing Practice) compliance certification for the production of Rigvir virus ECHO-7.
Read MoreNumerous viruses have been tested in clinical trials and three are approved. Our virus was the first.
Full PublicationMelanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential.
Read MoreThe investment will be used in accordance with the Rigvir science program to strengthen the product's scientific capacity.
Read MoreAdrenal gland melanoma is an extremely rare diagnosis with less than 20 cases reported.
Read MoreThe results suggest cytolytic activity of oncolytic ECHO-7 virus strain Rigvir in MP41, 92-1 and Mel-202 cell lines.
Read MoreA counterfeit of medicine Rigvir has been detected, which is being distributed in Russia, Ukraine, Kazakhstan and possibly other countries. Counterfeit medicines are easily identifiable visually.
Read MoreThis report describes a stage I uveal melanoma patient treated with oncolytic virus Rigvir as an adjuvant therapy.
Read MoreThis report describes a stage III glottic cancer patient treated with Rigvir therapy.
Read MoreWe are committed to prove, that the cancer treatment can be safe, effective and harmless.
Our CompanyIn the 1960s with the efforts of professor Aina Muceniece the focus points in the perception of cancer started to shift.
Our HistoryInnovations in biotechnological cancer treatments are the key concepts for improving the health quality of global population.
Focus AreasAccess the latest information regarding our company, people, science, partnerships and opportunities.
ExploreRigvir Group is committed to partner with global industry and business leaders in the fight against oncological illness.
ExploreContact us to receive a consultation and/or information about oncolytic virotherapy with ECHO-7 medicine.
Contact Us